Spiclomazine

Spiclomazine (Clospirazine) is a potent mutant KRAS (G12C) inhibitor that selectively inhibits mutant KRAS-driven pancreatic cancer. Spiclomazine can eliminate KRas-GTP levels in KRAS-driven pancreatic cancer and effectively inhibit RAS-mediated signaling. Spiclomazine significantly inhibits tumor progression in mouse renal capsule xenotransplantation models[1].

Product Specifications

CAS Number

[24527-27-3]

Product Name Alternative

Clospirazine

UNSPSC

12352005

Target

Ras

Type

Reference compound

Related Pathways

GPCR/G Protein; MAPK/ERK Pathway

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/spiclomazine.html

Purity

99.95

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1CSC2(CCN(CCCN3C4=C(C=CC=C4)SC5=CC=C(Cl)C=C35)CC2)N1

Molecular Formula

C22H24ClN3OS2

Molecular Weight

446.03

References & Citations

[1]Guo X, et al. Spiclomazine displays a preferential anti-tumor activity in mutant KRas-driven pancreatic cancer. Oncotarget. 2018 Jan 8;9 (6) :6938-6951.